Mithra files for bankruptcy and continues negotiations with Gedeon Richter for the sale of Neuralis and Estetra

  • On Monday morning, the Tribunal de l’Entreprise of Liège opened bankruptcy proceedings against Mithra Pharmaceuticals SA and appointed trustees
  • Mithra CDMO and Novalon SA entities are not affected by the bankruptcy as they are subject to separate judicial reorganization proceedings

 

Liège, Belgium, 10 June 2024 – 19:15 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that the Tribunal de l’Entreprise of Liège pronounced the opening of the bankruptcy procedure of Mithra Pharmaceuticals SA this morning.

Mithra Pharmaceuticals SA was indeed facing major financial difficulties which prevent it from fulfilling its obligations and no longer had the working capital required to pursue its activities.

As previously announced, Mithra Pharmaceuticals SA had entered into negotiations with Gedeon Richter. Mithra Pharmaceuticals announces today that it continues negotiations with Gedeon Richter relating to the sale to Gedeon Richter of all shares in Neuralis SA and Estetra SRL held by Mithra Pharmaceuticals SA and specific assets of Mithra R&D SA relating to the manufacture of estetrol. It is expected that the transaction would be signed and completed as soon as reasonably possible. The Mithra CDMO and Novalon SA entities are not affected by the bankruptcy as they are subject to separate judicial reorganization proceedings. The judicial protection measures to which they are subject should, subject to the court’s approval, be extended until 30 June 2024. This extension is intended to allow the different parties interested in Mithra CMDO’s assets to continue their due diligence and submit binding offers by mid-month.

The amount to be received from the sale of Neuralis SA and Estetra SRL as well as certain assets of Mithra R&D SA, after deduction of financial debts, will allow to repay some amounts to the creditors as per their legal privilege. As a result, this transaction does not create any value for the shareholders of Mithra Pharmaceuticals SA.

Mithra Pharmaceuticals SA was born of the ambition to significantly improve women’s health, Mithra has distinguished itself by the unwavering determination of its employees to push the boundaries of science for the common good. Their research and the progress it heralds will outlive Mithra and will continue under a different banner from now on. We all hope that these efforts will lead to the development of new solutions that will benefit as many people as possible.

The management and Board of Directors would like to thank Mithra’s shareholders and partners who have played a decisive role in the scientific advances that Mithra has made possible.

Disclaimer

Please read this carefully as it applies to all persons who visit this website. The following pages contain information relating to an offering and/or admission to trading on a regulated market in relation to securities of Mithra Pharmaceuticals SA ("Mithra Pharmaceuticals"). This information may not be accessed by residents of certain countries based on applicable securities law regulations. Accordingly, if you wish to access this part of the website you must first inform yourself about and then observe the statutory and regulatory requirements applicable to you and to your jurisdiction. In order to establish whether or not you may view the information and documents please read the disclaimer below in full.

THIS WEBSITE AND THE MATERIALS CONTAINED THEREIN ARE NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.

This website and the information contained herein or to which it gives access are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the "United States"), Australia, Japan or South Africa, and do not constitute, or form part of, an offer or invitation to sell or issue, or a solicitation of an offer or invitation to purchase or subscribe for, nor shall there be any sale or purchase of, any securities of Mithra Pharmaceuticals in the United States, Australia, Japan or South Africa or in any other jurisdiction in which such offer, invitation, solicitation, sale, issue, purchase or subscription would be unlawful prior to registration, unless an exemption from registration or qualification under the securities laws of any such jurisdiction is applicable. The securities of Mithra Pharmaceuticals referred to on this website have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act. There will be no public offering of Mithra Pharmaceuticals' securities in the United States.

All persons residing outside of the United States, Australia, Canada, Japan and South Africa who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. Mithra Pharmaceuticals assumes no responsibility if there is a violation of applicable law and regulations by any person.

No action has been taken by Mithra Pharmaceuticals that would permit an offer of Mithra's securities or the possession or distribution of the materials to which this website gives access or any other offering or publicity material relating to Mithra's securities in any jurisdiction where action for that purpose is required.

Mithra Pharmaceuticals has not authorised any public offering in any Member State of the European Economic Area. With respect to any Member State of the European Economic Area that has implemented Regulation 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended from time to time (together with any applicable implementing measures in such Member State, the "Prospectus Regulation"), this website and the information contained herein, or to which it gives access, is only addressed to, and is only directed at, qualified investors in that Member State within the meaning of the Prospectus Regulation.

In addition, in the United Kingdom, this website and the information contained herein, or to which it gives access, is addressed to, and directed only at: (a) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), and (b) high net worth entities, and other persons to whom they may otherwise lawfully be communicated, falling within article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). In the United Kingdom, any investment or investment activity to which this website and the information contained herein, or to which it gives access, relates, is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person in the United Kingdom who is not a Relevant Person should not act or rely on this website and the information contained herein, or to which it gives access.

If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. Access to electronic versions of these materials is being made available on this webpage by Mithra Pharmaceuticals in good faith and for information purposes only.

By checking the acceptance box below, you confirm and certify that: You are not a resident of or physically present in the United States, Australia, Canada, Japan or South Africa or any other restricted jurisdiction, and that you are either: (a) a resident of, and domiciled in, a Member State of the European Economic Area and a qualified investor within the meaning of the Prospectus Regulation, (b) a resident of, and domiciled in, the United Kingdom, a qualified investor within the meaning of the Prospectus Regulation and a Relevant Person, or (c) otherwise authorised to access this information pursuant to applicable laws or regulations.